Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 14Unknown 5Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 9Recurrence 1Oligodendroglioma 1Neoplasms 1Neoplasm Recurrence, Local 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Glioma 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 3Nivolumab 3pembrolizumab 2Temozolomide 2Surveys and Questionnaires 2Paclitaxel 2ONC206 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Etoposide 2Cyclophosphamide 2Carboplatin 2Biopsy 2regorafenib 1pegfilgrastim 1mirdametinib 1lutetium Lu 177 dotatate 1fludarabine 1etoposide phosphate 1entrectinib 1entinostat 1elacestrant 1decitabine and cedazuridine drug combination 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1aflibercept 1abemaciclib 1Topotecan 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Central Nervous System Neoplasms × Lomustine × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡